#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Gastrointestinal disorder Cerebral amyloid angiopathy Myocarditis Anti-neutrophil cytoplasmic antibody positive vasculitis Cushing's syndrome Crohn's disease ROHHAD syndrome Osteosarcoma Hypoxic-ischaemic encephalopathy Autologous haematopoietic stem cell transplant Primitive neuroectodermal tumour Antiphospholipid antibodies Lip and/or oral cavity cancer Myelofibrosis Chemical burn More trials…

    Learn about Rare Diseases

    Burkitt’s lymphoma – Trials in Disease Primary biliary cholangitis – Trials in Disease IgA nephropathy – Diagnostics Chondrosarcoma – Life with Disease Von Willebrand’s disease – Trials in Disease Nephroblastoma – Diagnostics Hereditary neuropathic amyloidosis Nephroblastoma – Trials in Disease Brain stem glioma Noonan syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    AMODIAQUINE Abemaciclib Glofitamab Azelastine Hydrochloride Pemetrexed Disodium Intestifix Epoetin Alfa Morf-057 Pitavastatin Calcium AZD6234 Tenofovir Disoproxil Fumarate PAPAVERINE HYDROCHLORIDE Molidustat Sodium Rbl016.2 Resamirigene Bilparvovec Ethanol, Anhydrous Sparsentan Poloxamer 407 4-Hydroxy-N-Desmethyltamoxifen Dexamethasone Phosphate More therapies…

    Learn about Your Condition

    Papillary thyroid cancer Sarcoma metastatic Cystic fibrosis lung Systemic scleroderma Syphilis Basal cell carcinoma Post cardiac arrest syndrome Post procedural complication Neurotrophic keratopathy Bronchopulmonary aspergillosis Oesophageal achalasia VEXAS syndrome Substance use disorder Bronchiolitis Meniere's disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Specjalistyczny Szpital Onkologiczny Nu-Med Sp. z o.o….

Specjalistyczny Szpital Onkologiczny Nu-Med Sp. z o.o.

Ul. Jana Pawla II 35, Tomaszow Mazowiecki, 97-200, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Carboplatin
    • Infliximab
    • Mycophenolate Mofetil
    Austria Belgium Czechia France Germany Hungary +5

  • Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Durvalumab
    • Glucose
    • Infliximab
    France Germany Italy Poland Portugal Spain

  • Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Cyclophosphamide
    Austria Belgium Bulgaria France Germany Hungary +3

  • Study on Rilvegostomig and Chemotherapy for Patients with Biliary Tract Cancer After Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Biliary cancer metastatic
    • Biliary neoplasm
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Gemcitabine
    Belgium Denmark France Germany Italy Norway +2

  • Study Comparing Datopotamab Deruxtecan to Chemotherapy in Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Datopotamab Deruxtecan
    • Eribulin Mesylate
    Belgium France Germany Hungary Italy Poland +1

  • Study of Durvalumab and Tremelimumab for Patients with Limited Stage Small-Cell Lung Cancer After Chemoradiation Therapy

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Dextrose Bp
    • Durvalumab
    • Infliximab
    Belgium Czechia Germany Italy The Netherlands Poland +1

  • Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Small cell lung cancer
    Investigated Drugs:
    • Irinotecan
    • Lurbinectedin
    • Topotecan
    Austria Belgium Bulgaria Denmark France Germany +5

  • Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Docetaxel
    • SIGVOTATUG VEDOTIN
    Austria Belgium Czechia France Germany Greece +7

  • Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Capivasertib
    • Fulvestrant
    Belgium Denmark France Germany Italy Poland +2

  • Study comparing trifluridine/tipiracil with bevacizumab versus capecitabine with bevacizumab as first-line treatment for patients with metastatic colorectal cancer who cannot receive intensive therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Capecitabine
    • Tipiracil Hydrochloride
    Denmark Poland Slovakia Sweden
Previous Page
1 2

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!